Nat Aging:阿尔兹海默症疫苗来了!2期临床试验有效诱导免疫应答

2021-06-15 haibei MedSci原创

这是一项为期24个月的双盲、平行臂、随机的2期多中心安慰剂对照试验,其中AADvac1是一种活性肽疫苗,旨在针对AD的病理性tau蛋白(EudraCT 2015-000630-30)。

阿尔兹海默症的神经病理学特征是淀粉样蛋白-β的沉积和tau蛋白的聚集。神经纤维性tau病理学与神经退行性过程的关键方面密切相关。神经纤维病变的分布和数量与脑萎缩的严重程度和模式,以及认知障碍和痴呆的临床表现和严重程度密切相关。目前,通过tau正电子发射断层扫描(PET)看到的神经纤维病理学的沉积模式,可以预测未来的脑萎缩和纵向认知能力的下降情况。

根据目前的理解,最初发生神经纤维病变的神经元会往外传播tau聚集体,这与朊病毒有相似之处。随后,随着受影响的神经元产生的tau种子进入健康但脆弱的细胞,在那里它们改变生理性的tau构象,tau病理沿着神经元通路在大脑中传播。因此,神经元的损害是通过tau的功能丧失和毒性功能增强的组合发生的。

越来越多的证据表明,聚集的tau,无论是以游离形式还是以外泌体形式,都可以通过各种途径从供体细胞(神经元或胶质细胞)转移到受体细胞,包括受体介导的(肝素硫酸酯蛋白多糖,LDL受体相关蛋白1)或非受体介导的内吞/微蛋白吞噬或通过纳米管运输(体外数据)。靶向tau是有潜力的AD治疗手段。

最近,研究人员报告了ADAMANT的结果,这是一项为期24个月的双盲、平行臂、随机的2期多中心安慰剂对照试验,其中AADvac1是一种活性肽疫苗,旨在针对AD的病理性tau蛋白(EudraCT 2015-000630-30)。

在试验过程中,有11个剂量的AADvac1被施用于轻度AD痴呆患者,每个剂量40微克。主要目标是评估长期AADvac1治疗的安全性和耐受性。次要目标是评估AADvac1治疗的免疫原性和减缓认知和功能衰退的疗效。

AADvac1治疗104周以上的抗体反应表明其具有强大的免疫原性。

共有196名患者在AADvac1和安慰剂之间进行了3:2的随机分组。结果显示,AADvac1安全且耐受性良好(AADvac1 n = 117,安慰剂n = 79;在17.1%的AADvac1治疗者和24.1%的安慰剂治疗者中观察到严重不良事件;在84.6%的AADvac1治疗者和81.0%的安慰剂治疗者中观察到不良事件)。该疫苗诱导了高水平的IgG抗体。在整个研究样本的认知和功能测试中没有发现明显的影响(临床痴呆评级-盒子量表调整后的平均点差-0.360(95% CI -1.306,0.589)),自定义认知调整后的平均Z分数差异为0.0008(95% CI -0.169,0.172)。

此外,研究人员还提出了探索性分析和事后分析的结果,研究特定亚组的相关生物标志物和临床结果。总之,该结果显示,AADvac1是安全和免疫原性的,但需要更大规模的分层研究来更好地评估其潜在的临床疗效和对疾病生物标志物的影响。

 

原始出处:

Petr Novak et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease. Nature Aging (2021). 

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-09-01 DR.Fu SIR

    有效性挺难的。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2022-03-12 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-06-23 121670d3m44(暂无昵称)

    安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1970274, encodeId=e35119e0274a1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1116, encryptionId=7cb11116d7, topicName=2期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Nov 01 21:15:56 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013471, encodeId=bdf810134e165, content=有效性挺难的。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Wed Sep 01 14:33:33 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885234, encodeId=8c7d1885234a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 12 15:15:56 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976313, encodeId=388b9e631358, content=安全性可以,认知功能没有改善,不知道扩大样本量是否能显示出差异, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d932251601, createdName=121670d3m44(暂无昵称), createdTime=Wed Jun 23 20:36:44 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400252, encodeId=184a14002528f, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402824, encodeId=b438140282433, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Thu Jun 17 08:15:56 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974128, encodeId=955f9e4128ae, content= 讨论了半天,论证了安全性,有效性还有待观察。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210427/b594a756d77e4171b5313e531ef89b43/31c000a8a97d4872b698c80fb8a33369.jpg, createdBy=624b2152505, createdName=大叔默默路过, createdTime=Wed Jun 16 16:15:01 CST 2021, time=2021-06-16, status=1, ipAttribution=)]
    2021-06-16 大叔默默路过

    讨论了半天,论证了安全性,有效性还有待观察。。

    0

相关资讯

Neurology: 遗传性阿尔茨海默病,脑内微出血预示痴呆风险增加

遗传性阿尔茨海默病,脑内微出血预示痴呆风险增加

Sci Trans Med:Tau抗体semorinemab I期临床安全

Semorinemab还显示了体内靶点参与的明确证据,在tau转基因小鼠、非人灵长类动物和人类中观察到全身tau浓度的增加。与健康对照组相比,AD参与者用药后观察到更高的全身tau浓度。

Nat Commun:耗竭B细胞可逆转阿尔茨海默病的进展

尽管表达了促进AD的转基因,但仅损失B细胞就足以减少Aβ斑块负担和疾病相关的小胶质细胞,此外,该疗法还分别逆转了行为和记忆障碍,并恢复了TGFβ+小胶质细胞。

Nat Commun:究竟是哪些基因变异导致我们更易得阿尔茨海默病?

研究人员首先通过合并所有可用的病例对照数据集和代理研究结果(发现人数=409,435,验证人数=58,190)进行了一项大型的遗传关联研究。

NEJM:礼来Aβ抗体二期临床结果公布:达到主要终点,错失次要终点

2021年3月13日,礼来的Aβ抗体Donanemab的二期临床结果在新英格兰杂志被公布(临床编号:NCT03367403)。